ArticleActa diabetologica2026

Could the heparanase/TGF-β axis modulation be considered for the SGLT2 inhibitors cardioprotection in obesity? A hypothesis-generating report.

Angelo Di Vincenzo et al.PubMed ↗Publisher ↗

No numbers read from the abstract.